CompletedNCT03854409
Official study titleAn Open-label, Single- and Multiple-dose, Pharmacokinetic, Safety, and Tolerability Trial of Aripiprazole Long-acting Injectable Administered in the Deltoid or Gluteal Muscle in Adult Subjects With Schizophrenia or Bipolar I Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockBipolarity, SchizophreniaMedication studyAges 18–64
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
WithdrawnACTRN12614000121662
Official study titleA trial of targeted repetitive Transcranial Magnetic Stimulation (rTMS) in the treatment of auditory hallucinations in schizophrenia
This study was withdrawn before enrollment.
In AustraliaSchizophreniaInterventional studyAges 18–75
- Countries
- Australia
- Sponsor
- Professor Paul Fitzgerald
Active Not RecruitingNCT06894212
What is this study about?Researchers are comparing SEP-363856 and placebo to find out how the approaches affect psychotic symptoms in people with schizophrenia.
This study is no longer accepting new participants.
Multiple locations, including BentonvilleSchizophreniaMedication studyAges 18–65
- Countries
- United States, Japan
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
CompletedNCT06229977
Official study titleA Randomized Controlled Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression
This study has finished and is no longer accepting participants.
In HoustonBipolarity, DepressionMedication studyAges 18–70
- Countries
- United States
- Sponsor
- Rodrigo Machado-Vieira, MD, PhD, MSc
CompletedNCT05593029
What is this study about?This study evaluated the safety and effectiveness of SEP-363856 for people with depression.
This study has finished and is no longer accepting participants.
Multiple locations, including BirminghamDepressionMedication studyAges 18–65
- Countries
- United States, Canada, Bulgaria, + 4 others
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
CompletedNCT06366438
Official study titleA Randomized Controlled Trial of Two Universal Programs for Parents of Teenagers: ABC (Face-to-face) vs. Parentweb (Online)
This study has finished and is no longer accepting participants.
Multiple locations, including BrommaMental healthBehavioural studyAges 13–19
- Countries
- Sweden
- Sponsor
- Karolinska Institutet
Active Not RecruitingNCT05102864
About this title
A Trial of Two-Week Brain Stimulation for Teenagers With ADHD
Read the official source — NCT05102864Official study titleA Trial of Two-Week Brain Stimulation for Teenagers With ADHD
This study is no longer accepting new participants.
In East ProvidenceADHDDevice studyAges 12–18
- Countries
- United States
- Sponsor
- Bradley Hospital
CompletedNCT06372210
Official study titleAn Open-label, Prospective Trial Assessing Positive Detection Accuracy and Detection Latency Measures of the Miniature Ingestible Event Marker Tablet Using the D-Tect Patch in Healthy Subjects and Assessing Detection Latency Measures Using the D-Tect Patch in Subjects With Serious Mental Illness Taking Abilify MyCite Tablet
This study has finished and is no longer accepting participants.
In Garden GroveDepression, Schizophrenia, ...Medication studyAges 18+
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
CompletedNCT03259555
What is this study about?Researchers compared Brexpiprazole and placebo to find out how the approaches affected manic symptoms in people with bipolarity type I during a manic episode.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockBipolarityMedication studyAges 18–65
- Countries
- United States, Bulgaria, Poland, + 1 other
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
CompletedNCT03257865
What is this study about?Researchers compared Brexpiprazole and placebo to find out how the approaches affected manic symptoms in people with bipolarity type I during a manic episode.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockBipolarityMedication studyAges 18–65
- Countries
- United States, Croatia, Ukraine
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
CompletedNCT07314333
Official study titleA Phase 1, Single Blind, Parallel-arm Trial to Assess the Potential for Pharmacodynamic Interaction of Centanafadine When Co-administered With Stimulants in Healthy Adults
This study has finished and is no longer accepting participants.
In Salt Lake CityADHDMedication studyAges 18–55
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)